Results from Phase III Trial of once-daily diazoxide choline controlled release (DCCR) tablets for patients with Prader-Willi Syndrome (PWS)

Study (n=127) did not meet primary endpoint of change from baseline to week 13 in hyperphagia (unrelenting hunger) vs. placebo. However, significant changes were observed in Clinical Global Impression of Improvement score (p=0.029) & reduction of body fat mass (p=0.025).

SPS commentary:

In the UK, diazoxide choline (an agonist of the ATP-sensitive potassium channel, or, KATP channel) is currently under investigation in Phase 3 clinical trials for PWS; the most commonly known genetic cause of life-threatening obesity.


Biospace Inc.